Skip to main content
REGENERON PHARMACEUTICALS, INC. logo

REGENERON PHARMACEUTICALS, INC. — Investor Relations & Filings

Ticker · REGN ISIN · US75886F1075 LEI · 549300RCBFWIRX3HYQ56 US Manufacturing
Filings indexed 1,720 across all filing types
Latest filing 2021-01-04 Regulatory Filings
Country US United States of America
Listing US REGN

About REGENERON PHARMACEUTICALS, INC.

https://www.regeneron.com/

Regeneron Pharmaceuticals, Inc. is an integrated biotechnology company that invents, develops, manufactures, and commercializes medicines for serious diseases. The company's research and development efforts are focused on a wide range of therapeutic areas, including ophthalmology, cancer, allergic and inflammatory diseases, cardiovascular and metabolic disorders, and rare diseases. Regeneron leverages its expertise in biologics and genetic medicines to translate scientific breakthroughs into transformative treatments for patients.

Recent filings

Filing Released Lang Actions
Regulatory Filings 2021
Regulatory Filings Classification · 90% confidence The provided document text appears to be encoded or encrypted and does not contain any readable content, keywords, regulatory headers, or references to specific report types, fiscal periods, or regulatory bodies. Without any meaningful text or context, it is impossible to classify this document as any specific filing type. Given the lack of identifiable information and the fallback rule, the appropriate classification is Regulatory Filings (RNS), which serves as a catch-all category for miscellaneous or unclassifiable filings.
2021-01-04 English
PRIMARY DOCUMENT
Director's Dealing
2020-12-31 English
PRIMARY DOCUMENT
Director's Dealing
2020-12-11 English
PRIMARY DOCUMENT
Director's Dealing
2020-12-11 English
PRIMARY DOCUMENT
Director's Dealing
2020-12-11 English
PRIMARY DOCUMENT
Director's Dealing
2020-12-11 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.